Inc., (OTCBB: ADXS), a leader in
developing the next generation of immunotherapies for cancer and
infectious diseases, announced that the first two dogs have been
dosed in the University of Pennsylvania School of Veterinary Medicine
study of ADXS-HER2 for canine osteosarcoma.
Under the direction of Dr. Nicola Mason, Chair in Companion Animal
Medicine at the University of Pennsylvania School of Veterinary
Medicine, ADXS-HER2 is being used to treat dogs suffering from bone
cancer. Canine osteosarcoma is a leading killer of large breed dogs that
causes tumors to form on long leg bones. The traditional treatment is
immediate amputation and, even with subsequent chemotherapy, the cancer
typically metastasizes to the lungs, causing death in 6-12 months.
In this trial, dogs that have undergone standard of care treatment for
osteosarcoma; including limb amputation and follow up chemotherapy, and
that over-express the tumor marker HER-2/neu in their tumors, are
treated with Advaxis agent ADXS-HER2. This immunotherapy is designed to
stimulate the dog's immune system to attack cancer cells that express
the HER-2/neu marker. The goal is to elicit anti-tumor immunity and
"We don't have to wait years to see if we are having an effect,"
commented Dr. Nicola Mason. "If we find that these canine patients
survive over 12 months, then that is a strong indication that this
immunotherapy is in fact providing a therapeutic benefit."
For more information about the study please visit the Mason
Bone Cancer Study webpage.
Links to press that the trial has attracted can be found in the events
and presentations section of the Advaxis
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next
generation of immunotherapies for cancer and infectious diseases.
Advaxis immunotherapies are based on a novel platform technology using
live, attenuated bacteria that are bio-engineered to secrete an
antigen/adjuvant fusion protein that is designed to redirect the
powerful immune response all human beings have to the bacterium to
the cancer itself.
In April 2012, Advaxis' lead construct, ADXS-HPV, was selected as the
Best Therapeutic Vaccine (approved or in development) at the 5th Annual
Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the
journal Expert Reviews of Vaccines. The ViE awards, sponsored by
Novartis Vaccines and Diagnostics, were created to recognize the
accomplishments and contributions of companies and individuals in the
vaccine industry over the previous 12 months. Additional information is
available at the World
Vaccine Congress website.
Advaxis' lead construct, ADXS-HPV, is being evaluated in 4 Phase 2
clinical trials that are open for enrollment for HPV-associated
diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier
NCT01116245), locally advanced cervical cancer (GOG/NCI US study,
Clinical Trials.gov Identifier NCT01266460), recurrent/refractory
cervical cancer (India), and head & neck cancer (CRUK study,
Clinical Trials.gov Identifier NCT01598792). Over fifteen (15) distinct
constructs are in various stages of development, developed directly by
the Company and through strategic collaborations with recognized centers
of excellence such as: the National
Cancer Institute, Cancer
Research - UK, the Wistar
Institute, the University
of Pennsylvania, the University
of British Columbia, the Karolinska
Institutet, and others. For more information please visit: advaxis.com
This news release contains forward-looking statements, including,
but not limited to: statements as to the anticipated timing of clinical
studies and other business developments, statements as to the
development of new constructs, expectations as to the adequacy of our
cash balances to support our operations for specified periods of time
and as to the nature and level of cash expenditures, expectations as to
market opportunities, our ability to take advantage of those
opportunities, and the risk factors set forth from time to time in
Advaxis' SEC filings, including but not limited to its report on Form
10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov.
The Company undertakes no obligation to publicly release the result of
any revision to these forward-looking statements which may be made to
reflect the events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events, except as required by law. You
are cautioned not to place undue reliance on any forward-looking
Diana Moore, 609-452-9814
Relations & Business Development